CRMD Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2024-03-05 | Lefkowitz Steven W | director | 30,000 | A-Award | A | 30,000 | 3.55 | 106,500.00 |
| 2024-03-05 | Stewart Robert A | director | 30,000 | A-Award | A | 30,000 | 3.55 | 106,500.00 |
| 2024-03-05 | Kaplan Myron | director | 30,000 | A-Award | A | 30,000 | 3.55 | 106,500.00 |
| 2024-03-05 | Dillione Janet | director | 30,000 | A-Award | A | 30,000 | 3.55 | 106,500.00 |
| 2024-03-05 | DUNTON ALAN W | director | 30,000 | A-Award | A | 30,000 | 3.55 | 106,500.00 |
| 2024-03-05 | Duncan Gregory Scott | director | 30,000 | A-Award | A | 30,000 | 3.55 | 106,500.00 |
| 2024-03-13 | Todisco Joseph | director, officer: Chief Executive Officer | 352,839 | P-Purchase | A | 13,561 | 3.74 | 50,718.00 |
| 2024-01-12 | Masson-Hurlburt Elizabeth | 0 | 0 | 0.00 | 0.00 | |||
| 2024-01-12 | Masson-Hurlburt Elizabeth | officer: EVP, Head of Clinical Ops. | 100,000 | A-Award | A | 100,000 | 3.47 | 347,000.00 |
| 2024-01-12 | Masson-Hurlburt Elizabeth | officer: EVP, Head of Clinical Ops. | 58,000 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2024-01-12 | Masson-Hurlburt Elizabeth | officer: EVP, Head of Clinical Ops. | 53,397 | F-InKind | D | 4,603 | 3.47 | 15,972.00 |
| 2024-01-12 | David Matthew T | officer: Chief Financial Officer | 100,000 | A-Award | A | 100,000 | 3.47 | 347,000.00 |
| 2024-01-12 | David Matthew T | officer: Chief Financial Officer | 53,150 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2024-01-12 | David Matthew T | officer: Chief Financial Officer | 47,934 | F-InKind | D | 5,216 | 3.47 | 18,100.00 |
| 2024-01-12 | Mistry Erin | officer: Chief Commercial Officer | 100,000 | A-Award | A | 100,000 | 3.47 | 347,000.00 |
| 2024-01-12 | Mistry Erin | officer: Chief Commercial Officer | 54,900 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2024-01-12 | Mistry Erin | officer: Chief Commercial Officer | 50,511 | F-InKind | D | 4,389 | 3.47 | 15,230.00 |
| 2024-01-12 | Todisco Joseph | director, officer: Chief Executive Officer | 353,059 | A-Award | A | 133,333 | 0.00 | 0.00 |
| 2024-01-12 | Todisco Joseph | director, officer: Chief Executive Officer | 339,278 | F-InKind | D | 13,781 | 3.47 | 47,820.00 |
| 2024-01-12 | Todisco Joseph | director, officer: Chief Executive Officer | 266,667 | A-Award | A | 266,667 | 3.47 | 925,334.00 |
| 2023-12-15 | DUNTON ALAN W | director | 15,250 | P-Purchase | A | 3,000 | 3.30 | 9,900.00 |
| 2023-12-14 | DUNTON ALAN W | director | 12,250 | P-Purchase | A | 3,000 | 3.45 | 10,350.00 |
| 2023-12-12 | Zelnick Kaufman Beth | officer: Chief Legal Officer | 200,000 | A-Award | A | 200,000 | 3.30 | 660,000.00 |
| 2023-12-12 | Zelnick Kaufman Beth | officer: Chief Legal Officer | 50,000 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2023-12-12 | Zelnick Kaufman Beth | 0 | 0 | 0.00 | 0.00 | |||
| 2023-11-17 | Mistry Erin | officer: Chief Commercial Officer | 4,900 | P-Purchase | A | 1,000 | 4.00 | 4,000.00 |
| 2023-11-16 | Lefkowitz Steven W | director | 75,498 | M-Exempt | A | 15,000 | 2.25 | 33,750.00 |
| 2023-11-16 | Lefkowitz Steven W | director | 0 | M-Exempt | D | 15,000 | 2.25 | 33,750.00 |
| 2023-09-08 | Todisco Joseph | director, officer: Chief Executive Officer | 219,726 | P-Purchase | A | 10,000 | 3.71 | 37,100.00 |
| 2023-05-18 | Kaplan Myron | director | 166,034 | P-Purchase | A | 6,000 | 4.54 | 27,258.00 |
| 2023-05-17 | Costa Paulo F | director | 10,000 | P-Purchase | A | 10,000 | 4.65 | 46,500.00 |
| 2023-05-17 | DUNTON ALAN W | director | 9,250 | P-Purchase | A | 3,000 | 4.33 | 12,980.00 |
| 2023-05-17 | Stewart Robert A | director | 11,000 | P-Purchase | A | 10,000 | 4.37 | 43,735.00 |
| 2023-05-17 | Todisco Joseph | director, officer: Chief Executive Officer | 209,726 | P-Purchase | A | 5,000 | 4.58 | 22,900.00 |
| 2023-05-17 | Costa Paulo F | director | 10,000 | A-Award | A | 10,000 | 4.65 | 46,500.00 |
| 2023-05-17 | DUNTON ALAN W | director | 9,250 | A-Award | A | 3,000 | 4.33 | 12,980.00 |
| 2023-05-17 | Stewart Robert A | director | 11,000 | A-Award | A | 10,000 | 4.37 | 43,735.00 |
| 2023-05-17 | Todisco Joseph | director, officer: Chief Executive Officer | 209,726 | A-Award | A | 5,000 | 4.58 | 22,900.00 |
| 2023-05-10 | Todisco Joseph | director, officer: Chief Executive Officer | 204,726 | F-InKind | D | 37,443 | 5.30 | 198,448.00 |
| 2023-04-13 | Stewart Robert A | director | 25,000 | A-Award | A | 25,000 | 5.25 | 131,250.00 |
| 2023-04-13 | Stewart Robert A | director | 14,200 | A-Award | A | 14,200 | 5.25 | 74,550.00 |
| 2023-04-13 | Stewart Robert A | director | 1,000 | D | 0 | 0.00 | 0.00 | |
| 2023-01-14 | Mistry Erin | officer: Chief Commercial Officer | 75,000 | A-Award | A | 75,000 | 0.00 | 0.00 |
| 2023-01-15 | Mistry Erin | officer: Chief Commercial Officer | 3,900 | D | 0 | 0.00 | 0.00 | |
| 2023-01-14 | Todisco Joseph | officer: Chief Executive Officer | 400,000 | A-Award | A | 400,000 | 0.00 | 0.00 |
| 2023-01-14 | Mounts Phoebe | officer: General Counsel | 125,000 | A-Award | A | 125,000 | 0.00 | 0.00 |
| 2023-01-14 | Lefkowitz Steven W | director | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2023-01-14 | Dillione Janet | director | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2023-01-14 | Kaplan Myron | director | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2023-01-14 | Masson-Hurlburt Elizabeth | officer: EVP, Head of Clinical Ops. | 125,000 | A-Award | A | 125,000 | 0.00 | 0.00 |
| 2023-01-14 | DUNTON ALAN W | director | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2023-01-14 | Duncan Gregory Scott | director | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2023-01-14 | David Matthew T | officer: Chief Financial Officer | 125,000 | A-Award | A | 125,000 | 0.00 | 0.00 |
| 2023-01-14 | Costa Paulo F | director | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2022-11-15 | Todisco Joseph | officer: Chief Executive Officer | 242,169 | P-Purchase | A | 20,000 | 3.82 | 76,400.00 |
| 2022-08-24 | Todisco Joseph | director: Chief Executive Officer | 222,169 | P-Purchase | A | 4,700 | 3.92 | 18,424.00 |
| 2022-05-17 | Kaplan Myron | director: | 160,034 | P-Purchase | A | 5,000 | 3.78 | 18,900.00 |
| 2022-05-16 | Todisco Joseph | director: Chief Executive Officer | 217,469 | P-Purchase | A | 10,000 | 3.38 | 33,800.00 |
| 2022-05-10 | Todisco Joseph | director: Chief Executive Officer | 207,469 | A-Award | A | 207,469 | 0.00 | 0.00 |
| 2022-03-18 | Todisco Joseph | 0 | 0 | 0.00 | 0.00 | |||
| 2022-02-22 | Dillione Janet | director | 20,000 | A-Award | A | 20,000 | 4.03 | 80,600.00 |
| 2022-02-22 | Costa Paulo F | director | 20,000 | A-Award | A | 20,000 | 4.03 | 80,600.00 |
| 2022-02-22 | Duncan Gregory Scott | director | 20,000 | A-Award | A | 20,000 | 4.03 | 80,600.00 |
| 2022-02-22 | DUNTON ALAN W | director | 20,000 | A-Award | A | 20,000 | 4.03 | 80,600.00 |
| 2022-02-22 | Lefkowitz Steven W | director | 20,000 | A-Award | A | 20,000 | 4.03 | 80,600.00 |
| 2022-02-22 | Kaplan Myron | director | 20,000 | A-Award | A | 20,000 | 4.03 | 80,600.00 |
| 2022-02-18 | Nusbickel Thomas | officer: EVP, Chief Commercial Officer | 100,000 | A-Award | A | 100,000 | 4.03 | 403,000.00 |
| 2022-02-18 | Masson-Hurlburt Elizabeth | officer: EVP, Head of Clinical Ops. | 100,000 | A-Award | A | 100,000 | 4.03 | 403,000.00 |
| 2022-02-18 | Mounts Phoebe | officer: General Counsel | 140,000 | A-Award | A | 140,000 | 4.03 | 564,200.00 |
| 2022-02-18 | David Matthew T | officer: Interim CEO and CFO | 100,000 | A-Award | A | 0 | 4.03 | 0.00 |
| 2021-12-27 | Kaplan Myron | director | 155,034 | G-Gift | D | 20,000 | 0.00 | 0.00 |
| 2021-12-27 | Kaplan Myron | director | 150,034 | G-Gift | D | 5,000 | 0.00 | 0.00 |
| 2021-12-27 | Kaplan Myron | director | 145,034 | G-Gift | D | 5,000 | 0.00 | 0.00 |
| 2021-12-27 | Kaplan Myron | director | 140,034 | G-Gift | D | 5,000 | 0.00 | 0.00 |
| 2021-12-06 | David Matthew T | officer: Interim CEO and CFO | 3,150 | P-Purchase | A | 1,000 | 4.50 | 4,500.00 |
| 2021-12-06 | David Matthew T | officer: Interim CEO and CFO | 3,150 | P-Purchase | A | 1,000 | 4.50 | 4,500.00 |
| 2021-11-16 | Kaplan Myron | director | 175,034 | P-Purchase | A | 10,000 | 5.14 | 51,400.00 |
| 2021-11-17 | David Matthew T | officer: Interim CEO and CFO | 2,150 | P-Purchase | A | 1,000 | 5.07 | 5,070.00 |
| 2021-11-01 | David Matthew T | officer: Interim CEO and CFO | 125,000 | A-Award | A | 125,000 | 5.56 | 695,000.00 |
| 2021-11-01 | Mounts Phoebe | officer: General Counsel | 100,000 | A-Award | A | 0 | 5.56 | 0.00 |
| 2021-05-21 | Masson-Hurlburt Elizabeth | officer: EVP, Head of Clinical Ops | 0 | S-Sale | D | 8,000 | 6.92 | 55,394.00 |
| 2021-05-13 | Nusbickel Thomas | officer: EVP, Chief Commercial Officer | 260,000 | A-Award | A | 260,000 | 7.56 | 1,965,600.00 |
| 2021-05-13 | Nusbickel Thomas | officer: EVP, Chief Commercial Officer | 7,500 | A-Award | A | 7,500 | 7.56 | 56,700.00 |
| 2021-05-13 | Nusbickel Thomas | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2021-05-17 | Kaplan Myron | director | 165,034 | P-Purchase | A | 15,000 | 6.03 | 90,477.00 |
| 2021-01-11 | ARMSTRONG JR. JOHN L. | officer: Exec VP of Tech Operations | 140,000 | A-Award | A | 140,000 | 8.32 | 1,164,800.00 |
| 2021-01-11 | Masson-Hurlburt Elizabeth | officer: EVP, Head of Clinical Ops. | 140,000 | A-Award | A | 140,000 | 8.32 | 1,164,800.00 |
| 2021-01-11 | DUNTON ALAN W | director | 30,000 | A-Award | A | 30,000 | 8.32 | 249,600.00 |
| 2021-01-11 | Lefkowitz Steven W | director | 30,000 | A-Award | A | 30,000 | 8.32 | 249,600.00 |
| 2021-01-11 | Kaplan Myron | director | 30,000 | A-Award | A | 30,000 | 8.32 | 249,600.00 |
| 2021-01-11 | Duncan Gregory Scott | director | 20,000 | A-Award | A | 20,000 | 8.32 | 166,400.00 |
| 2021-01-11 | Dillione Janet | director | 30,000 | A-Award | A | 30,000 | 8.32 | 249,600.00 |
| 2021-01-11 | Costa Paulo F | director | 20,000 | A-Award | A | 20,000 | 8.32 | 166,400.00 |
| 2021-01-11 | Baluch Khoso | director, officer: Chief Executive Officer | 320,000 | A-Award | A | 320,000 | 8.32 | 2,662,400.00 |
| 2021-01-11 | Mounts Phoebe | officer: General Counsel | 140,000 | A-Award | A | 140,000 | 8.32 | 1,164,800.00 |
| 2021-01-11 | David Matthew T | officer: Chief Financial Officer | 80,000 | A-Award | A | 80,000 | 8.32 | 665,600.00 |
| 2020-11-16 | Dillione Janet | director | 3,583 | A-Award | A | 3,583 | 0.00 | 0.00 |
| 2020-11-02 | Duncan Gregory Scott | director | 20,000 | A-Award | A | 20,000 | 5.00 | 100,000.00 |
| 2020-11-02 | Duncan Gregory Scott | director | 2,500 | A-Award | A | 2,500 | 5.00 | 12,500.00 |
| 2020-11-02 | Duncan Gregory Scott | 0 | 0 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
